Omega Fund Management, LLC
CIK 1637359 · View on SEC EDGAR ↗
- Portfolio value
- $185.7M
- Positions
- 10
- As of
- June 30, 2026
Portfolio value QoQ: +13.8% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 8
- Effective number of positions
- 5.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.03% Est. buys $54,128 · sells $18,833,101
Median holding: 5.0 quarters Tracked Q4 2024–Q2 2026 · 58.8% still held
- New positions
- 1
- Increased
- 0
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +3.0% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 99.1% · Options excluded: 0.0%
Sector breakdown
Full portfolio 10 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics Inc. - Common Stock | $54,099,634 | 29.14% | 1,822,150 | $6,519,770 | Down ×1 | ||
| NUVB Nuvation Bio Inc. Class A Common Stock | $45,900,586 | 24.72% | 8,081,089 | $11,232,714 | |||
| KMTS Kestra Medical Technologies, Ltd. - Common Stock | $26,003,471 | 14.00% | 1,022,149 | $5,632,041 | |||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $25,067,217 | 13.50% | 3,289,661 | $-4,375,249 | |||
| BBNX Beta Bionics, Inc. - Common Stock | $20,624,588 | 11.11% | 1,316,183 | $7,436,434 | |||
| ALMS Alumis Inc. - Common Stock | $6,788,916 | 3.66% | 241,255 | $1,474,068 | |||
| SANA Sana Biotechnology, Inc. - Common Stock | $2,944,688 | 1.59% | 843,750 | $514,688 | |||
| IMA ImageneBio, Inc. - Common Stock | $2,686,630 | 1.45% | 455,361 | $409,825 | |||
| ENGN enGene Holdings Inc. - Common Stock | $1,516,098 | 0.82% | 876,357 | $-4,451,893 | |||
| Unknown issuer (CUSIP: 67613T104) | $54,128 | 0.03% | 2,893 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 67613T104) | $54,128 | 2,893 | 0.03% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| NUVB | Price move only | +0 | +$11.2M |
| BBNX | Price move only | +0 | +$7.4M |
| BCAX | Trimmed | -570K | +$6.5M |
| KMTS | Price move only | +0 | +$5.6M |
| ENGN | Price move only | +0 | -$4.5M |
| BBOT | Price move only | +0 | -$4.4M |
| ALMS | Price move only | +0 | +$1.5M |
| SANA | Price move only | +0 | +$515K |
| IMA | Price move only | +0 | +$410K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| UPB | March 31, 2026 | 1,326,293 | $36,008,855 | -19.0% |
| LXEO | Sept. 30, 2025 | 1,184,636 | $4,762,237 | -21.5% |
| IKNA | Sept. 30, 2025 | 2,249,123 | $3,013,825 | No longer tracked |
| REPL | June 30, 2026 | 248,672 | $1,909,801 | 28.7% |
| IMUX | Sept. 30, 2025 | 1,788,160 | $1,248,136 | 1776.4% |
| ENGNW | Dec. 31, 2025 | 89,702 | $63,438 | |
| SYRS | March 31, 2025 | 251,270 | $57,792 | No longer tracked |